Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
CLOVER-1
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
- NCT02952508 ↗
- Active, not recruiting
- Cellectar Biosciences, Inc.
- Focused
We haven't built an HCP commentary report on CLOVER-1 (iopofosine I-131 (CLR 131) in relapsed or refractory select B-cell malignancies) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on CLOVER-1 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 | |
| YouTube | 2 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- An Open-Label, Multicenter, Phase 2 Study of Iopofosine I 131 (CLR 131) in Patients With Relapsed or Refractory (R/R) Select B-Cell Malignancies (CLOVER-1) and Expansion Cohort in Patients With Waldenstrom Macroglobulinemia (CLOVER-WaM)
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Waldenstrom Macroglobulinemia; Multiple Myeloma; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Lymphoplasmacytic Lymphoma; Marginal Zone Lymphoma; Mantle Cell Lymphoma; Diffuse Large B Cell Lymphoma; Central Nervous System Lymphoma
- Interventions
- Iopofosine I 131 single dose; Iopofosine I 131 multiple dose; Iopofosine I 131 fractionated dose
- Arms
- Iopofosine I 131, intravenous administration WM · Experimental
- Iopofosine I 131, intravenous administration MM · Experimental
- Iopofosine I 131, intravenous administration CNS Lymphoma · Experimental
- Iopofosine I 131 intravenous administration NHL [CLOSED] · Experimental
- Enrollment
- 120 (estimated)
- Primary outcomes
- Part A [CLOVER-1] Clinical benefit rate
- Part B [CLOVER-WaM] Major Response Rate
- Sponsor
- Cellectar Biosciences, Inc.
- Start
- Jul 26, 2017
- Primary completion
- Jun 22, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT02952508 · updated Mar 18, 2026